Ionis Pharmaceuticals Inc news

   Watch this stock
Showing stories 11 - 20 of about 97   

Articles published

IONS 29.18 +0.99 (3.51%)
price chart
Ionis Pharmaceuticals Inc. (IONS) Earns Market Perform Rating from Leerink Swann
Ionis Pharmaceuticals logo Ionis Pharmaceuticals Inc. (NASDAQ:IONS)'s stock had its “market perform” rating reaffirmed by Leerink Swann in a research note issued on Monday.
Keep an eye on Analyst Actions: Ionis Pharmaceuticals Inc (NASDAQ:IONS ...  Street Updates
Delta Air Lines, Inc. (NYSE:DAL) & Ionis Pharmaceuticals (NASDAQ:IONS ...  Money News (press release)
Why Ionis Pharmaceuticals Inc Couldn't Hold Its Price Today
What: Ionis Pharmaceuticals (NASDAQ:IONS) was down as much as 13% today, although it's pulled back a bit in midday trading after announcing that the Food and Drug Administration put a clinical hold on a clinical trial, dubbed CARDIO-TTR, being run by ...
Ionis Pharmaceuticals Inc Under Pressure on Clinical Hold by FDA  Bidness ETC
Ionis: Catalyst Pending, Ignore The Drop  Seeking Alpha
/quotes/zigman/3870025/realtime
Ionis Pharmaceuticals Inc. NASDAQ: IONS. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.
Why Ionis Pharmaceuticals Inc Plunged 36% in January
Ionis presented at the JP Morgan Healthcare conference, where it announced that its 2015 net operating loss was going to come in "in the low $20 million range," representing a 60% improvement over its original guidance.
Hot Stock under Consideration: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
The Company gained 11.26% and finished at $27.28. The daily volume was measured at 5.43 million shares. The 52-week high of the share price is $65.34 and the 52-week low is $19.59.
Ionis Pharmaceuticals Inc: New Name, Same Waiting Game
Ionis Pharmaceuticals (NASDAQ:IONS) released fourth-quarter earnings on Thursday, the first time since renaming itself from Isis Pharmaceuticals, but it was business as usual at the biotech, with management more focused on the pipeline than the ...
Ionis Pharmaceuticals, Inc. Crashed Another 12% in February -- Here's Why
What: Shares of Ionis Pharmaceuticals (NASDAQ:IONS) (previously Isis Pharmaceuticals), a predominantly clinical-stage drug developer utilizing its antisense technology platform to create therapies for a variety of diseases, lost 12% of its value in ...
Ionis Pharma - Stock Down, Products Moving Along: A Reassessment  Seeking Alpha
Ionis Pharmaceuticals Inc Takes It to the Extremes
What: Ionis Pharmaceuticals (NASDAQ:IONS) was down as much as 10.5% today. It seems the reason for the drop was because today isn't Thursday.
Why BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc, and ImmunoGen ...
What: BioMarin Pharmaceutical (NASDAQ:BMRN), Ionis Pharmaceuticals (NASDAQ:IONS), and ImmunoGen (NASDAQ:IMGN) all fell almost 10% today for apparently no reason.
Ionis Pharmaceuticals Inc (IONS) Sees Significant Increase in Short Interest
Ionis Pharmaceuticals logo Ionis Pharmaceuticals Inc (NASDAQ:IONS) was the recipient of a significant growth in short interest during the month of June.
Stock Tracing Lower on the Week Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)  Engelwood Daily